{
    "answer": "KISQALI is approved in combination with an AI.",
    "ground_truth": "Treating hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer (adjuvant)",
    "rewards": [
        0,
        0
    ],
    "reward_sum": 0,
    "turns": 2,
    "search count": 1,
    "script count": 0,
    "summary count": 0,
    "context lengths": [
        857,
        2345
    ]
}